Cannabis (Albuquerque, N.M.)最新文献

Objective: Trauma survivors are more likely than others to use cannabis, and post-traumatic stress disorder (PTSD) commonly co-occurs with cannabis use disorder (CUD). Automatic memory associations between trauma reminders and cannabis use have been suggested as contributing mechanisms. These associations can be studied experimentally by manipulating trauma cue exposure in a cue-reactivity paradigm (CRP) and examining effects on the accessibility of cannabis information in memory in trauma survivors with and without PTSD.

Method: Cannabis users with trauma histories (N = 202) completed a PTSD measure (PTSD Checklist-5) and were randomized to a trauma or neutral expressive writing task as an online CRP. Next, participants completed a cue-behavior word association task, which involved presentation of a series of ambiguous cue words to which participants provided the first word that came to mind. Some of these ambiguous cues pertained to cannabis (e.g., weed, pot) and some to other substances (e.g., blow, shot). This task was scored by two independent raters. Linear regression models tested the hypothesized main and interactive effects of CRP condition (trauma, neutral) and PTSD group (probable PTSD, no PTSD) on the number of cannabis and other substance responses generated.

Results: Main effects of CRP condition were found for cannabis responses (b = 0.41, p = .048; trauma > neutral) but not other substance responses. Unexpectedly, no main effects or interactions of PTSD group were observed for either outcome.

Conclusions: In cannabis users with trauma histories, writing about one's trauma specifically activates greater accessibility of cannabis-related information in memory, regardless of PTSD.

Objective: An increase in medical cannabis and prescribed cannabinoids use for chronic pain management has been observed in Canada in the past years. This study aimed to: 1) Describe clinicians' perceived risk associated with the use of medical cannabis and prescribed cannabinoids for the management of chronic pain; and 2) Identify sociodemographic and professional factors associated with perceived risk of adverse effects.

Method: A web-based cross-sectional study was conducted in Quebec, Canada in 2022. A convenience sample of 207 clinicians was recruited (physicians/pharmacists/nurse practitioners). They were asked to rate the risk of adverse effects associated with medical cannabis (e.g., smoke, or oil) and prescribed cannabinoids (e.g., nabilone) on a scale of 0 to 10 (0: no risk, 10: very high risk), respectively. Multiple linear regression was performed to identify factors associated with perceived risk.

Results: Average perceived risk associated with medical cannabis and prescribed cannabinoids were 5.93 ± 2.08 (median:6/10) and 5.76 ± 1.81 (median:6/10). Factors associated with higher medical cannabis perceived risk were working in primary care (β = 1.38, p = .0034) or in another care setting (β = 1.21, p = .0368) as compared to a hospital setting. As for prescribed cannabinoids, being a pharmacist (β = 1.14, p = .0452), working in a primary care setting (β = 0.83, p = .0408) and reporting more continuing education about chronic pain (β = 0.02, p = .0416) were associated with higher perceived risk. No sex differences were found in terms of perceived risk.

Conclusions: Considering the clinician's experience provide insights on cannabis risk as these professionals are at the forefront of patient care when they encounter adverse effects.

Objective: Little is known about the population-level impact of recreational cannabis legalization on trends in opioid-related mortality. Increased access to cannabis due to legalization has been hypothesized to reduce opioid-related deaths because of the potential opioid-sparing effects of cannabis. The objective of this study was to examine the relations between national retail sales of recreational (non-medical) cannabis and opioid overdose deaths in the 5 years following legalization in Canada.

Method: Using time-series data, we applied Granger causality methods to evaluate the association between trends in legal recreational cannabis sales and opioid-related deaths over time. Both sales and opioid deaths grew over time, with the latter exhibiting significant increases following the onset of the COVID-19 pandemic.

Results: We found no support for the hypothesis that increasing post-legalization sales Granger caused changes in opioid-related deaths in British Columbia, Ontario, or at the national level.

Conclusions: These findings suggest that increases in legal recreational cannabis sales following legalization were not meaningfully associated with changes in opioid-related mortality. Further examination with longer follow-up periods will be needed as the legal cannabis market becomes more entrenched in Canada, but these findings converge with previous work suggesting legalization is not related to opioid overdose mortality and further undermine that hypothesized link as a basis for legalization in other jurisdictions.

Although Canada legalized cannabis beverages in 2019, most available research on acute cannabis intoxication derives from dried flower and edible products. The distinct bioavailability and pharmacokinetic properties of phytocannabinoids ingested from beverages, however, contribute to significantly different acute and long-term effects that need to be better understood to ensure consumer safety.

Objective: This review investigates existing cannabis beverage literature, with a particular focus on acute intoxication effects.

Method: PubMed, PsycINFO and Web of Science databases were systematically searched. A structured search generated 29 eligible studies, comprising studies of consumption patterns and beliefs, advertisements and marketing, acute effects in human models, and drink composition.

Results: Human studies report aversive acute subjective and physiological effects induced by cannabis beverages in healthy, infrequent users. Beverages also showed inaccurate cannabinoid labeling, posing potential risks to consumers. This review highlights the paucity and inconsistency of available research, further exacerbated by the sheer diversity of formulations investigated, while beginning to address some questions surrounding the safety and risks associated with cannabis beverages.

Conclusions: Given the extensive differences in effects across cannabis-infused beverages, and the growing 'drinkables' market, it is essential that more studies directly examine both acute and long-term impacts of cannabis beverage consumption.

Objective: Since the federal Canadian government legalized cannabis in 2018, cannabis use in the general population has slightly increased. However, little is known about the impact of cannabis legalization on pattens of cannabis use in psychiatric populations.

Method: We studied changes in daily/almost daily and average 30-day cannabis use amongst individuals currently using cannabis who reported past 12-month experiences of specific mental health disorders and among those without past 12-month experiences of any mental health disorder before and after Canadian legalization of recreational cannabis use (N = 13,527). Data came from Canadian respondents in Wave 1 (August-October 2018), Wave 2 (September-October 2019), and Wave 3 (September-November 2020) of the International Cannabis Policy Study (ICPS).

Results: After adjustment for covariates, among individuals currently using cannabis, the odds of using cannabis daily/almost daily increased only in individuals with schizophrenia between Wave 1 and Waves 3 (aOR = 9.19, 95% CI: 2.46 - 34.37). Similarly, significant increases in average 30-day cannabis use between Wave 1 (M = 12.80, SE = 1.65) and Wave 3 (M = 18.07, SE = 1.03) were observed only among individuals with schizophrenia, F (1,2) = 4.58, p < .05. No significant changes in daily/almost daily or average past 30-day cannabis use were observed in those without mental health problems or those reporting anxiety, depression, PTSD, bipolar disorder, or substance use disorders.

Conclusions: Since legalization, cannabis use has significantly increased only among people with schizophrenia, highlighting the need for targeted public health prevention programs.

Objective: People living with chronic pain increasingly use medical cannabis for symptom relief. We conducted a retrospective cohort study examining cannabis for chronic pain relief using anonymous archival data obtained from the medicinal cannabis tracking app, Strainprint®.

Method: We acquired cannabis utilization data from 741 adults with chronic pain and used multilevel modeling to examine the association of age, sex, type of pain (muscle, joint or nerve pain), cannabis formulation (high CBD, balanced CBD:THC, or high THC), route of administration (inhaled or ingested), cannabis use before vs. during the COVID-19 pandemic, and duration of cannabis use, with pain relief.

Results: Most patients were female (n = 464; 63%), with a mean age of 39 (SD = 11), and our cohort had completed a total of 83,622 tracked cannabis sessions through Strainprint. The majority of sessions reported use of inhaled cannabis products (78%), typically with high tetrahydrocannabinol (THC; 64%) versus high cannabidiol (CBD; 15%) or balanced THC:CBD (21%) products. The median change in pain scores across sessions was -3.0 points on a 10-point numeric rating scale (NRS; IQR -4.5 to -2.0). In our adjusted model, greater pain relief was associated with male vs. female sex (-0.69 points on a 10-point NRS; 95%CI -0.46 to -0.91). We found statistically significant, but trivial associations with joint pain (-0.05 points), balanced THC:CBD products in the long term (-0.003 points), and cannabis use during the pandemic (0.18 points).

Conclusions: We found that people living with chronic pain report important pain relief when using cannabis for medical purposes, and that men may achieve greater pain relief than women.

Objective: Cannabis has become more available in Canada since its legalization in 2018. Many individuals who use cannabis also use alcohol (co-use), which can be used either at the same time such that their effects overlap (simultaneous use) or at different times (concurrent use). Though studies have identified predictors of co-use relative to single-substance use, less is known about the predictors of specific types of co-use. The present study examined the mental health and dispositional predictors of simultaneous relative to concurrent use of the two legal substances (cannabis and alcohol) among adults in Canada.

Method: Canadian adults reporting past-year use of both cannabis and alcohol (N = 1,761) were recruited from Academic Prolific and six Canadian universities. Participants completed online self-report measures of demographic characteristics, cannabis and alcohol co-use, mental health symptoms, impulsivity, and personality traits.

Results: Binary logistic regression analyses revealed that when independent variables were each examined individually, greater severity of depression, anxiety, PTSD, and ADHD symptoms; greater negative urgency and lack of premeditation; and greater impulsivity each predicted an increased likelihood of reporting past-year simultaneous use relative to concurrent use. When independent variables were grouped into three separate models (mental health, impulsivity, and personality variables), greater anxiety symptom severity, ADHD symptom severity, negative urgency, and sensation seeking were each uniquely associated with an increased likelihood of simultaneous relative to concurrent use.

Conclusions: Individuals with elevated anxiety and ADHD symptoms, as well as negative urgency and sensation seeking, may be more inclined to engage in simultaneous use to self-medicate and achieve greater symptom reduction. Future studies may examine the directionality of these relations and motives (e.g., coping) that may differentiate simultaneous and concurrent use.

Objective: Recent studies found that recreational legalization of cannabis consumption for Canadian adults has increased presentation to the emergency department (ED) among children. In this descriptive study, our objectives were to (1) understand Canadian pediatric emergency medicine (PEM) providers' training and knowledge of clinical presentations associated with cannabis exposure in children and (2) describe pediatric ED presentations related to cannabis exposure across Canada following legalization in 2018.

Method: In 2021, following ethics board approval, 230 Pediatric Emergency Research Canada (PERC) network pediatric emergency medicine (PEM) physicians were invited to share about their knowledge, training, and experience with patients presenting with cannabis-associated emergencies using an anonymized survey administered through REDCap.

Results: In total, 84/230 (36.5%) invited physicians completed the survey. Almost 70% of the PEM physicians reported an increase in the number of cannabis-associated ED presentations they have seen since legalization, while only 15% reported no increase in presentations. More than 90% of the respondents reported an average or higher level of knowledge of cannabis-associated pediatric emergencies. More than half (n = 48, 57%) were interested in pursuing further training, preferring formal training opportunities. The main presentations to the ED were decreased level of consciousness, known unintentional (accidental) ingestion and vomiting. Significantly more tests were ordered when cannabis consumption was unknown at the beginning of the assessment, compared to when it was known, however, treatment plans were the same (mainly supportive measures).

Conclusions: Most PEM providers are managing an increasing number of cannabis-associated ED presentations. PEM providers should improve communication with caregivers around household cannabis use. When caregivers feel comfortable disclosing cannabis presence at home, it can help prevent unnecessary tests and interventions for their children if they present to the ED.

Objective: In October 2018, the Government of Canada legalized cannabis for recreational use nationwide. The effects of legalization on cannabis use have been primarily assessed through cross-sectional surveys.

Method: In the present study, a two-wave longitudinal design was used to explore potential demographic, substance use and behavioral addiction, and mental health predictors of change in cannabis use status following legalization. Canadian online panelists (18+) were initially surveyed about their gambling and substance use in 2018 (i.e., before cannabis legalization). From the original sample, 4,707 (46.2%) were retained in the follow-up survey one year later, post-cannabis legalization. These respondents were the focus of the present study.

Results: When queried about how legalization would impact their use, 61.8% said, 'I'll never use it', 21.1% stated "I'll use it about the same as I do now," 10.3% indicated, "I may try it for the first time," 5.0% answered, "I'll use it more," and 1.9% responded that, "I'll use it less." Consistent with these sentiments, within the retained sample there was a modest but significant increase in cannabis use from baseline (18.4%) to follow-up (26.1%). Regressions established that younger age, being male, substance use, tobacco or e-cigarette use, problematic gambling, and stated intention to use cannabis were predictors of later cannabis use.

Conclusions: This national cohort design indicates that cannabis use appears to have increased in Canada following legalization. The present study makes a unique contribution by also identifying variables that statistically forecast movement toward and away from cannabis use.

Objective: The relationship between cannabis use and mental health has garnered significant attention in recent decades. However, studies have largely been in general populations or in countries in which recreational cannabis use is illegal.

Method: The current cross-sectional study examines the relationship between cannabis use, mood disorders, anxiety, and psychosis in an inpatient psychiatric population with severe concurrent mental health and substance use disorders, exploring the potential moderating effect of the legalization of recreational cannabis in Canada.

Results: Cannabis use compared to non-use was associated with higher self-reported depression, anxiety, and psychotic symptoms but was not associated with diagnosis of a mood, anxiety, or psychotic disorder. Frequency of cannabis use was unrelated to mental health outcomes, but age of first use was negatively associated with self-reported psychoticism symptoms. There were some significant associations between recreational cannabis legalization and mental health, but legalization was largely unrelated to outcomes. There were also some significant differences by demographics.

Conclusions: While findings are relatively consistent with prior literature, some significant associations differed, suggesting the importance of examining concurrent disorder patients as a unique population when examining relationships between cannabis use and mental health.